About IntelliGenome

At IntelliGenome, we develop diagnostic technology for the world’s serious health challenges and we are engineering a diagnostic platform that transforms the lives of people impacted by infectious disease. 

Our team is in pursuit of a future where point-of-care disease diagnosis is not only accurate, affordable and rapid, but also an instrument of positive transformation, particularly in low-and-medium income countries.

The IntelliGenome team has developed the first molecular diagnostic detection assay in the world using CRISPR technology to detect low abundance nucleic acid in small volume blood samples. 

We have also developed a high-efficiency DNA polymerase-based and thermostable protein-enhanced CRISPR fluorescence detection system, and further developed an ultra-sensitive approach to detect TB cell-free DNA in blood samples, which is an isolation-free, multiplex recombinase polymerase amplification (RPA)-CRISPR detection assay and a portable device to read point of care (POC) test results. 

  The first commercialization of our technology is a high-throughput tuberculosis laboratory diagnostic test, capable of delivering accurate and reliable results in hours. 

Our CRISPR-based platform can rapidly and accurately be adapted to combat future infectious disease outbreaks ranging from Nontuberculous Mycobacterium (NTM) infections to other emerging diseases in real time. 

As our platform evolves, our planned product roadmap includes developing multiplex capability to detect multiple diseases simultaneously to improve clinical response to complex diagnoses.